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Septic shock, defined by the need to use vasopressor to maintain mean blood 
pressure above 65mmHg after adequate infusion of fluids, associated with a 
serum lactate level above 2mmol/L, is the most common type of shock among 
hospitalized patients and an important cause of morbidity and mortality in 
Brazil and worldwide.(1,2) In Brazil, the incidence of septic shock has increased 
in recent years; the 28-day mortality rate has reached approximately 50%, with 
an incidence density of 30 cases per thousand patients/day. According to the 
PROGRESS study, the overall lethality rate of septic shock is 49.6%; in Brazil, 
it is estimated that this rate reaches approximately 67%, with even higher rates 
in public hospitals.(1-9)
A prevalence study in 230 Brazilian intensive care units (ICUs) found that 
30% of ICU beds in Brazil were occupied by patients with severe sepsis or 
septic shock.(1,9) According to a report by the Instituto Latino Americano da 
Sepse (ILAS), 42.2% of patients hospitalized in public and private Brazilian 
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Objective: To evaluate the short-
term evolution of patients with septic 
shock refractory to norepinephrine 
treated with vasopressin in an intensive 
care unit of a university hospital.
Methods: An unmatched 
retrospective study (case series) was 
performed. Clinical, laboratory, and 
anthropometric data were collected 
from patients who received vasopressin 
infusion for treatment of catecholamine-
refractory shock from December 2014 
to June 2016. For the assessment of 
severity, APACHE II and SOFA scores 
were used. The main outcome was 
mortality at 3 and 30 days.
Results: A total of 80 patients were 
included, of which 60% were male. In 
86.3% of the cases, APACHE II was 
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observed in the highest ranges (> 20). 
The 30-day mortality was 86.2%, and 
75% of the patients died within 72 
hours after starting vasopressin.
Conclusion: The series evaluated 
had high mortality in the first 72 
hours of treatment with vasopressin. 
The use of vasopressin in patients who 
are refractory to norepinephrine had 
little or no impact on mortality. It was 
not possible to exclude the possibility 
that the high mortality in the present 
study was linked to the relatively late 
onset (after established refractoriness 
of norepinephrine) of vasopressin; this 
hypothesis should be further evaluated 
in a randomized study.
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hospitals in July 2015 died of complications and severity 
of sepsis.(10,11) The mortality rate for septic shock with 
usual treatment (catecholamine use) varies in the range 
from 40 - 60%.(12)
Infusion of vasopressors in septic patients should 
be instituted whenever volume expansion is not 
sufficient to restore blood pressure and reverse organ 
dysfunction.(6) According to international guidelines, 
the use of norepinephrine is recommended as the first 
choice vasopressor (recommended dose of 0.05 to 2µg/
kg/min). A significant proportion of patients, however, do 
not achieve an adequate clinical response. Observational 
randomized clinical studies have shown that the 
administration of low doses of vasopressin in septic shock 
patients who are refractory to fluid replacement and the 
use of catecholamines may raise blood pressure and reduce 
the use of catecholamines; other potential physiological 
benefits are highlighted, such as a reduced risk of renal 
failure and arrhythmias.(13-15)
Thus, despite lacking high quality evidence showing 
a benefit in mortality, septic shock treatment guidelines 
recommend the addition of low dose vasopressin, 
corresponding to 0.03 - 0.04 International Units (IU)/
minute, to norepinephrine as a therapeutic alternative 
in refractory cases, with the intention of increasing the 
mean arterial pressure (MAP) and decreasing the dose 
of norepinephrine.(16) However, the effect of vasopressin 
on mortality remains controversial.(17) More studies are 
needed to determine the best treatment strategy as well 
as which groups of patients would benefit most from the 
association of vasopressor with different mechanisms of 
action in this situation.
The present study aimed to evaluate the short-term 
evolution of patients with septic shock refractory to 
norepinephrine treated with vasopressin, in terms of 
mortality and length of stay in the ICU. The secondary 
objective was to describe the clinical characteristics of 
a series of cases with shock refractory to the first line of 
treatment.
METHODS
An observational study of an unmatched retrospective 
design was performed. Data from patients who were 
hospitalized in the period from December 2014 to June 
2016 were analyzed. Patients aged 18 years and older who 
were hospitalized in any hospital unit and started using 
vasopressin for the treatment of septic shock were included 
in the study. According to hospital policy, vasopressin in 
only released for the treatment of septic shock in cases 
that are refractory to norepinephrine, as defined by the 
attending physician. The patients were identified through a 
computerized prescription report, and those with a registry 
of dispensing and administration of vasopressin infusion 
were included. Data were collected on anthropometric 
measurements, baseline disease, duration of vasopressor 
use, presence of organ dysfunction, and complications. 
Patient data were collected directly from the electronic 
medical record, and evolution data were recorded until 
hospital outcome (discharge or death) or for up to 30 days 
after starting treatment with vasopressin.(18)
For the assessment of severity and likelihood of 
complications, the Acute Physiology and Chronic Health 
Evaluation II (APACHE II, obtained at the time of 
initiation of vasopressin therapy) and Sequential Organ 
Failure Assessment (SOFA) scores were recorded.(19-21) 
To evaluate the correlation of mortality with SOFA, the 
Mann-Whitney test was used for independent samples.
The main outcomes were mortality at 3 and 30 days 
and length of ICU stay.
Data were collected using a standardized form, 
included in an Excel® database, and analyzed quantitatively 
through the Statistical Package for Social Sciences (SPSS) 
software. The study was approved by the Research Ethics 
Committee of the Hospital de Clínicas de Porto Alegre 
(project: 150592; CAAE 51721915700005327).
RESULTS
A total of 80 patients were included with a mean age 
of 55 years, and there was a predominance of the age 
group 61 years or older (42.5%), most of whom were men 
(60%). The clinical and demographic data of the sample 
are described in table 1. Most patients (86.3%) presented 
an APACHE score above 20 points; the median SOFA 
score obtained on the day of determined norepinephrine 
refractoriness was 11 points (25% percentile: 9; 75%: 13).
In all cases, the use of vasopressin followed the use of 
norepinephrine, which was used as the first option, in the 
usual dosage of 1µg/kg/minute.
The mean duration of norepinephrine treatment prior 
to initiation of vasopressin was 5 days. Vasopressin was 
used, on average, for 3 days, and the use was interrupted 
by death in most cases. At the time vasopressin was 
started, hemodialysis was performed in 26.3% of cases, 
and ventilatory failure was observed in 92.5% of cases.
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Hypotension (< 65mmHg) 45
Lactate levels
Normal (1.0mmol/L to 1.8mmol/L) 22.5
High 73.8
Not informed 3.8
SOFA, p = 0.238
Survivors up to 72 hours 10
Deaths up to 72 hours 11
APACHE - Acute Physiology and Chronic Health Evaluation; SVO2 - mixed venous saturation; 
SOFA - Sequential Organ Failure Assessment Score. * Patients had no defined infection 
focus or it was not possible to identify these data in the medical record. Results expressed 
as % or median.
points and 78.3% in the range of >20 points. The same 
was observed using the SOFA score;(22,23) a median of 11 
(25% percentile: 9% and 75: 13) was observed in the 
group that died within 72 hours, and a median of 10 
(25% percentile: 8 and 75%: 12.75) was observed in the 
group that survived (p = 0.238).
DISCUSSION
Vasopressin was incorporated into the hospital’s 
drug list in 2014 at the request of the Heart Transplant 
Service. Its use was approved for cases of shock associated 
with vasoplegia in the postoperative period of cardiac 
surgery. After inclusion on the list, however, vasopressin 
has also been prescribed in refractory cases of septic 
shock, especially in adults. In this way, the Pharmacy 
and Therapeutics Commission decided to evaluate the 
standard of use of the drug and its effectiveness when it 
was used outside the initially approved indication.
In the present study, a high mortality within 30 
days was observed in patients who used vasopressin for 
the treatment of septic shock refractory to the use of 
norepinephrine. In fact, in several localized studies, 
mortality was lower than that observed in the present 
series. In the meta-analysis performed by Polito et al.,(16) 
40.6% mortality was verified in 512 septic patients who 
used vasopressin. However, that meta-analysis included 
studies in which vasopressin was used as a first-line therapy, 
while the present series evaluated its use in a situation of 
refractoriness to norepinephrine.
In a meta-analysis of randomized trials (32 studies, 
3,544 patients) conducted by Avni et al.,(24) the effect 
of different vasopressors on the total mortality of adult 
patients with septic shock was evaluated. With the 
exception of norepinephrine, which was associated 
with decreased mortality from all causes compared with 
dopamine (relative risk - RR 0.89; 95% confidence interval 
- 95%CI 0.81 - 0.98), no differences were observed in 
mortality among the different treatments. Hemodynamic 
outcomes were similar among the various vasopressors, 
with some superiority of norepinephrine in central venous 
pressure in urinary output and in lactate levels.
In a meta-analysis of randomized trials (9 studies, n = 
998), Serpa Neto et al.(25) observed a decrease in the need 
for norepinephrine among patients receiving vasopressin 
or  terlipressin  compared  with controls  (standard  mean 
difference  1.58, 95%CI  -1.73 - -1.44); p < 0.0001). In 
that study, the effect estimates are provided in combination 
for users of vasopressin and terlipressin.
Sixty patients (75%) died within 72 hours of initiation 
of vasopressin infusion. The 30-day mortality rate was 
86.2% (Tables 2 and 3). There was no association between 
APACHE II score in relation to the incidence of death, 
with a lethality rate of 81.8% in the range of zero to 19 
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Table 2 - Results (n = 80)
Results
Days of use of norepinephrine (dose of 1µg/kg/min*)
1 - 5 66.3
6 - 20 31.3
21 - 30 2.5
Days of use of vasopressin (dose of 0.03 - 0.04 IU/min*)
1 - 5 95
6 - 20† 5
Days of ICU stay
1 - 5 48.8
6 - 20 36.3
21 - 30 5.0
31 or more‡ 10.0
Survival after vasopressin use 80 (%)
1 - 5 days 59 (73.8)
6 - 20 days 10 (12.5)
21 - 30 days 1 (1.3)
31 days or more‡ 10 (12.5)
Evolution in 3 days after use of vasopressin (in relation to 








Use of auxiliary therapy
Total with at least one auxiliary therapy 98.8
Renal replacement 3.8
Invasive mechanical ventilation 3.8
Use of corticosteroids 5.0
Use of two auxiliary therapies 52.5
Use of three auxiliary therapies 33.7
Not informed 1.2
Period of introduction of vasopressin treatment
After 48 hours of onset of sepsis 36.3
Ignored 1.3




Related to sepsis 76.3
Other reasons 12.5
ICU - intensive care unit. * Unit referring to the dosage of medicines; † prescription 
authorized by the Drugs Commission of the Clinics Hospital of Porto Alegre; ‡ the length of 
hospital stay in the intensive care unit and the survival of patients over 30 days (maximum 
study period) cannot be stated. Results expressed as n (%).
Table 3 - Clinical evolution of patients who survived after 72 hours (n = 19)




Results expressed as %.
Despite the limitations of APACHE II for predicting 
death, its use was approved given its widespread 
application in clinical practice as a parameter for severity 
and prognosis.(19,26) The APACHE II score obtained after 
the analysis of cases showed that the highest incidence of 
death was in the range of > 20 points (69 patients), while 
the incidence of death in the range from zero to 19 points 
included 11 patients.
The follow-up of the individual evolution of patients 
through the medical records of the hospital occurred 
until the hospital outcome (discharge or death) or for a 
maximum period of 30 days after starting treatment with 
vasopressin.(27,28) Therefore, for the patients who survived 
for a period of more than 30 days, the final outcome is not 
known, which may be considered as a limitation of the 
study. Among patients who survived more than 72 hours, 
only 18.8% showed improvement. This finding provide 
an explanation for why randomized clinical trials usually 
have a short follow-up time, as in the case of the studies 
by Malay et al.(14) and Patel et al.,(15) with follow-up times 
of 4 and 24 hours, respectively. However, there are other 
cases with a prolonged follow-up, such as in the study by 
Russell et al.(17) in which mortality was assessed at 28 and 
90 days.
Another limitation is that during the study, detailed 
measurements of important hemodynamic and metabolic 
outcomes, such as blood levels of lactate, cytokines, and 
troponins, were not performed; thus, there is the need for 
further studies to evaluate these variables. It was chosen 
not to evaluate these parameters in detail but instead to 
evaluate a “difficult” outcome (mortality). The clinical 
response to the vasopressor effect was evaluated through 
MAP.(15)
Given the uncontrolled design, this study can 
be considered to be predominantly exploratory and 
hypothesis-generating in nature; in fact, based on 
these data, it is not possible to establish the efficacy of 
vasopressin for reducing mortality. The study is, however, 
considered useful for reflections on clinical practice, given 
the frequent use of vasopressin in this context, despite the 
lack of good quality evidence in situations of refractoriness.
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CONCLUSION
Early mortality was elevated in septic patients with 
refractory shock treated with vasopressin. The high rate 
of therapeutic failure may have been due to the severity 
profile of the baseline disease; another possibility 
could be the relatively late introduction of vasopressin. 
However, the association of vasopressin with first-line 
catecholamines has not been shown to be effective in 
clinical studies.
Objetivo: Avaliar a evolução em curto prazo de pacientes 
com choque séptico refratário à norepinefrina tratados com va-
sopressina em uma unidade de terapia intensiva de um hospital 
universitário.
Métodos: Foi realizado estudo retrospectivo não comparado 
(série de casos). Foram coletados dados clínicos, laboratoriais e 
antropométricos de pacientes que receberam infusão de vaso-
pressina para tratamento de choque refratário a catecolaminas 
no período de dezembro de 2014 a junho de 2016. Para a ava-
liação de gravidade, foram utilizados o APACHE II e o SOFA. 
O desfecho principal foi mortalidade em 3 e em 30 dias.
Resultados: Foram incluídos 80 pacientes, sendo 60% do 
sexo masculino. Em 86,3% dos casos, verificou-se APACHE II 
nas faixas mais altas (> 20). A mortalidade em 30 dias foi de 
86,2%, sendo que 75% dos pacientes foram a óbito dentro de 
72 horas após início do uso da vasopressina.
Conclusão: A série avaliada apresentou alta mortalidade nas 
primeiras 72 horas de tratamento com vasopressina. O uso de 
vasopressina em pacientes refratários à norepinefrina teve pouco 
ou nenhum impacto na mortalidade. Não é possível excluir que 
a alta mortalidade no presente estudo esteja vinculada ao início 
relativamente tardio (após estabelecida refratariedade à norepine-
frina) da vasopressina, devendo essa hipótese ser melhor avaliada 
por estudo randomizado.
RESUMO
Descritores: Sepse; Mortalidade; Hipotensão; Vasopressina; 
Norepinefrina
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